Biomerieux SA operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biomerieux SA with three other
pharmaceutical manufacturers in Europe:
sales of 19.65 billion Swedish Kronor [US$2.20 billion]
of which 62%
Stada Arzneimittel AG
(2.12 billion Euro [US$2.30 billion]
of which 58%
was Generics), and
H. Lundbeck A/S
based in Denmark
(14.59 billion Danish Kroner [US$2.13 billion]
of which 22%
was Other Pharmaceuticals).
Biomerieux SA reported sales of 1.96 billion Euro (US$2.14 billion)
December of 2015.
increase of 15.7%
versus 2014, when the company's sales were 1.70 billion Euro.
Sales at Biomerieux SA have increased during each of the previous five years
(and since 2010, sales have increased a total of 45%).
Sales of Diagnostic Clinical Equipment saw an increase
that was more than double the company's growth rate: sales were up
374.6% in 2015, from
327.00 million Euro to 1.55 billion Euro.
Biomerieux SA also saw significant increases in sales in
Biofire Defense (up 106.7% to 24.80 million Euro)
Not all segments of Biomerieux SA experienced an increase in sales in 2015:
sales of Microbiological Industrial Equipment fell 73.2% to 362.70 million Euro.
Biomerieux SA also experienced decreases in sales in
Co-Development Program (down 2.9% to 6.80 million Euro)